Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2015 · 10-Q
Revenue$7.89M$7.89M−19.0% vs Q3 2014 Net Income$126.61K$126.61K−83.0% vs Q3 2014 EPS Diluted$0.01$0.01−75.0% vs Q3 2014 Operating Income$270,884−72.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$451,151−77.9% Margins · derivedOperating margin3.4%−6.7 pt vs Q3 2014
Net margin1.6%−6.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 6, 2015 · 37 d after period end